We administered the serotonin-1a agonist buspirone (0.4 mglkg orally) as a neuroendocrine challenge agent to a group of male patients with DSM-III -R major depressive disorder (MOD) (n = 13) and a group of male healthy controls (n = 10). The primary hypothesis of the study was that the prolactin response to buspirone would be blunted in the depressed patients. The prolactin response was significantly lower in depressed patients than in controls. There was no significant relationship between KEY WORDS: Depressive disorder; Serotonin; Buspirone; Prolactin 655 Avenue of the Americas, New York, NY 10010 placebo corrected-peak prolactin level and severity of depression or suicidality. There was a nonsignificant trend for the melancholic (n = 5) depressed patients to have a lower placebo corrected-peak prolactin level than nonmelancholic depressed patients (n = B).
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Our findings support a role for the serotonin-1a receptor in the etiology of MOD, specifically at the postsynaptic site. [NeuTopsychopharmacology 10:75-B3, 1994} reduced 5-HT function in patients with depression us ing 5-HT precursors (Charney et al. 1984; Heninger et al. 1984) , 5-HT reuptake inhibitors (Golden et al. 1992) , and 5-HT -releasing agents (Siever et al. 1984; Coccaro et al. 1989; Mitchell and Smythe 1990; Lichtenberg et al. 1992; Shapira et al. 1992a Shapira et al. , 1992b .
There has been a relatively consistent ii.nding of de creased prolactin response to various serotonergic agents in subjects with major depressive disorder (MOD) using nonspecific 5-HT challenge agents; thus, recent research has focused on the role of specific subtypes of 5-HT receptors in this response and whether the blunted prolactin response is measuring a presynaptic or postsynaptic phenomenon.
Several preclinical lines of evidence support a significant role for the 5-HTla receptor in MOD. Good win and colleagues (1985) found that a variety of an tidepressant treatments including selective 5-HT up take inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, and electroconvulsive shock all at tenuate the presynaptic hypothermic response to the 5-HT la agonist 8-hydroxy-2-( di-n-propylamino )tetralin (8-0H-OPAT) in the rat. Using electrophysiologic tech niques, induding measurement of presynaptic &ring rate in the dorsal raphe, as well as postsynaptic &ring 0893-133X/94/$7.00 rate in the hippocampus. Blier and de Montigny (1990) demonstrated that a variety of antidepressant treat ments all increased tonic activation of postsynaptic 5-HTla receptors. Another recent study found that 5-HTla receptor number in the frontal cortex of the rat as measured by 8-0H-DPAT binding was decreased by both chronic antidepressant treatment and electrocon vulsive shock (Pandey et al. 1991) .
This response to antidepressant treatment by the 5-HTla receptor is different from that of the 5-HTz receptor, which is upregulated by ECS and downregu lated by antidepressant medications (Peroutka and Snyder 1980) . Further preclinical support for a central role for the 5-HTla receptor in MOD comes from the fact that 5-HTla agonists are effective antidepressants in animal models of depression such as learned help lessness and the forced swim test (Wieland and Lucki 1990; Cervo and Samanin 1987; Martin et al. 1990 ).
Human studies also give some evidence of involve ment of the 5-HTla receptor in patients with MOD. Al though the 5-HTla agonist buspirone was originally marketed as an anxiolytic, one study found that buspi rone decreased symptoms of MOD (Rickels et al. 1991 ).
More recently, the bus pirone analogs gepirone and ip sapirone have also been found to possess some an tidepressant effects (Rausch et al. 1990 , Amsterdam et al. 1992 Lesch et al. 1991) . Two recent neuroendocrine challenge studies using the 5-HT la agonist ipsapirone also lend support for differences in 5-HTla receptor function in MOD. The frrst study found that the hypo thermic response to ipsapirone was attenuated after amitriptyline treatment (Lesch et al. 1990 ). The second study by the same group found a blunted ipsapirone induced adrenocorticotrophic hormone (ACTH) re sponse in patients with MOD compared to controls (Lesch et al. 1991) . Both of these studies are interest ing; however, the results of these studies are difficult to interpret in light of the fact that the hypothermic re sponse may be a presynaptic autoreceptor response (Lesch et al. 1991) , and the ACTH response is thought to be postsynaptic (Meltzer et al. 1983 ).
To further examine the role of postsynaptic 5-HT la receptor function in MOD, we administered the 5-HTla agonist and dopamine (DA) antagonist buspirone as a neuroendocrine challenge agent to a group of patients with MOD and a group of healthy controls. Buspirone was chosen as the neuroendocrine challenge agent be cause it does not bind to other 5-HT receptors in physi ologic concentrations and is well tolerated as a challenge agent in humans. Busiprone's drawback as a challenge agent is that it does bind to DA receptors as well as 5-HT receptors; it is possible that at least part of the neuroen docrine effects of bus pirone are due to its effects on DA.
The hypothesis of this study was that patients with MOD would show a blunted prolactin (postsynaptic) response compared to control subjects. Buspirone and placebo challenges were administered in a random sequence. Each challenge consisted of a single dose of either buspirone (0.4 mg/kg) or placebo administered orally. All subjects were on a low mono amine diet for 72 hours prior to each challenge. Sub jects and staff administering the rating scales were blinded to the medication condition. The subjects were given a standard light breakfast at 9:00 AM consisting of a can of Ensure (Ross Laboratories, Columbus, OH) prior to the challenge drug. Buspirone is more readily absorbed with food; thus, the subjects were not fast ing. It was also thought best not to fast subjects to min imize "stressful nausea," which has been reported to increase serum prolactin in healthy controls ). All subjects were kept supine and awake for the duration of the challenge. On the day of the neu roendocrine challenge, the subjects entered the Psy chobiology Laboratory of the Dallas V A Medical Cen ter Hospital prior to 8:30 AM. Shortly after the patient arrived, a catheter was inserted intravenously and an infusion of normal saline was initiated at the lowest rate necessary to keep the infusion open. One hour and 45 minutes after the insertion of the catheter, the frrst blood sample was drawn through a three-way stop cock to measure serum prolactin. Approximately 1 cc of blood was withdrawn and discarded prior to obtaining sam ples that were used in the study to eliminate any dilu tion effects of the normal saline. Two hours after the insertion of the catheter, the second baseline prolactin and cortisol levels were measured. After the second baseline blood drawing, the subject received the chal lenge drug consisting of either placebo or 0.4 mg/kg of bu spirone. There was a 2-hour delay after insertion of the catheter to allow for stabilization of hormone levels (Davis et al. 1985) . Blood drawing was repeated at 15-minute intervals from 10:45 AM till 1:00 PM. The sched ule for blood drawing included the period of increase in neuroendocrine parameters in previous studies (Meltzer et al. 1983 ). Approximately 10 cc of blood was drawn at each time point. The total amount of blood drawn did not exceed 150 cc per challenge day or 500 cc per month. The subject'S blood pressure and pulse were measured before and after each challenge.
Assays Analysis
Prolactin measurements were made on serum. Prolac tin was chosen instead of other hormones, such as cor tisol or ACTH because in our experience, the prolactin response to buspirone is the most robust (FG Moeller, unpublished data). Samples were centrifuged, and se rum was separated and frozen within 1 hour after the blood was drawn. After separation, samples were stored in a refrigerator at -30°C until analysis. Sam ples were analyzed within 2 months of collection by a technician blind to subject diagnosis. Prolactin was de termined in serum using a "coated tube" radio immu noassay with a monoclonal prolactin antibody immobi lized on the tube wall.
Subject samples are incubated with 1 25I-labeled prolactin in antibody coated tubes for 2 hours with ro tation (180 ± 10 rpm) after which the tubes are decanted to separate free prolactin from antibody-bound prolac tin, which is counted in a gamma counter. This assay is usable over a broad range (0 to 100 ng/rnl) and has a sensitivity of 0.3 ng/rnl. Coefficients of variation are typically 6% at 8 ng/rnl, 5% at 20 ng/rnl, and 5% at 45 ng/rnl.
Buspirone assays were done according to a modm cation of the method of Franklin (1990) , using gepirone as an internal standard. The resolution and sensitivity were determined by spiked plasma samples at 1.0, 5.0, and 10.0 ng/rnl. The samples were observed to be lin ear and proportional in this range. The interassay vari ability was 8.6%, and the recovery of buspirone (2.5 ng/rnl) ranged from 70% to 77%.
Statistical Analysis
Between group differences in mean age, buspirone lev els, and HDRS-D scores were analyzed using the Stu dent's t-test. The relationship between HDRS-D scores and peak prolactin levels within the depressed subjects 
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14.59 ± 10.32 3.27 ± 2.68** was analyzed using a regression analysis. Repeated measures analysis of variance (ANOV A) was performed on the prolactin levels over time to test the primary hy pothesis that the prolactin response to buspirone was different between the two diagnostic groups. Two depressed subjects and one control were dropped from the repeated-measures analysis because of missing prolactin levels at one or two time points. The prolac tin response to buspirone was placebo corrected by sub tracting the prolactin response to placebo from the prolactin response to buspirone. This was repeated for all time points in both depressed patients and controls. Prolactin levels were placebo corrected to adjust for any nonspecmc effects on prolactin secretion, such as food.
Because there was a nonsignihcant trend for a difference in age between depressed subjects and con trols, the influence of age was fIrst examined by includ ing age, group, and the age-group interaction in the ANOVA model.
This was done to test the underlying assumption of homogeneity of within group regression. Repeated measures analysis of covariance (ANCOV A) was per formed to determine if age was a signmcant covariate for prolactin response to buspirone.
RESULTS
Depressed patients were signmcantly more depressed than controls at the time of the fIrst neuroendocrine challenge as measured by the 17-item HDRS-D (t = 10.88, P < .0001). There was a nonsignmcant trend for age to differ between the depressed and control groups (t = 1.84, P = .08), see Table 1 .
Using repeated-measures ANOV A, there was a signmcant main effect of group on the prolactin re sponse between depressed patients and controls over time (F[l, 18] = 9.4; P = .007; Figs. 1 and 2 ). Bonferroni corrected post-hoc analyses revealed a signihcant diff er ence between the prolactin response of depressed pa tients and controls at 11:30 AM, 11:45 AM, 12:00 noon, 12:15 PM, 12:30 PM, 12:45 PM, and 1:00 PM (Fig. 3) . Be cause there was no signmcant interaction between age and group over time, (F[l,l1] ate was performed. There was no signifIcant interac tion between age and response to buspirone over time by repeated-measures ANCOV A with age as the covar iate F[l,11] = 0.879; P = .562. Using ANOV A, there was a signifIcant difference between the depressed pa- tients and controls in placebo corrected peak prolactin response (F[1,21] = 14.6; P = .001). To determirle the relationship between behavioral symptoms and neuroendocrine response within de pressed subjects, the placebo corrected peak prolactin level was used in a regression analysis with HDRS-D scores. There was no signifIcant relationship between prolactin level and severity of depression as measured by the HDRS-D (r2 = 0.035; P = .54). Patients were then subdivided into DSM-III-R melancholic (n = 5) and nonmelancholic (n = 8) subtypes, with the hypothesis that the melancholic subtype would have signifIcantly lower neuroendocrine response, as has been reported previously .
Melancholic patients appeared to have a lower peak prolactin (1.48 ± 1.82) than nonmelancholic patients (4.38 ± 2.59), and the three lowest peak prolactin lev els were in patients with melancholic depression. Using a t-test to compare the mean prolactin level between the melancholic and nonmelancholic patients, there was a nonsignifIcant trend for the melancholic group to have a lower peak prolactin level (t = -2.18; P = .052). How ever, this trend was not present in post-hoc contrasts when using an ANOV A that included the control group (F[1,20] = 0.509; P = .484; Fig. 4) .
Because of the previous report of a link between neuroendocrine response to a 5-HT challenge agent and history of suicidal behavior (Coccaro et al. 1989) , we examined the relationship between history of sucidial To determine if the blunted prolactin response to buspirone in the patient group was due to decreased absorption of buspirone, we compared the area under the curve (AVC) for buspirone blood levels between depressed patients and controls. Depressed patients had signiftcantly higher bus pirone blood levels (AVC 623.4 ± 519.0) than controls (AVC 241.5 ± 99.0) (t = -2.28; P < .05). The relationship between buspirone blood levels and peak prolactin response was deter mined by the Pearson correlation for all subjects and for depressed and control groups individually. For the study population as a whole, there was no significant correlation between bus pirone blood level and peak prolactin response (r = -0.04; P = .85). There was also no correlation between bus pirone blood level and prolactin response in controls (r = 0.32; P = .38). How ever, there was a signiftcant correlation between buspi rone blood level and peak prolactin response within the group of depressed subjects (r = 0.56; P = .05; Fig. 5 ). their results as consistent with the prolactin response to bus pirone being mediated both by 5HT la agonist and DA antagonist effects or possible pharmacokinetic interactions between bus pirone and pindolol. Other researchers fmd no effect of pretreatment with the 5-HTla antagonist pindolol on prolactin secretion in duced by buspirone (Meltzer et al. 1992) . Although some studies (Meltzer et al. 1992 ) report that the neuroendocrine effects of buspirone in humans are not blocked by pindolol pretreatment, this does not neces sarily mean that the neuroendocrine effects are not mediated by 5-HT. Other investigators have reported that pindolol is a mixed agonist/antagonist at the 5-HTla receptor (Hjorth and Carlsson 1986) and that behavioral effects of 5-HTla agonists are not reversed by pindolol in mice (Sanchez et al. 1993 ). We have also examined the effect of pretreatment with pindolol on the neuroendocrine effects of buspirone in normal con trols . We found that pindolol did not block the increase in hormone release induced by buspirone, in fact, pin dolol itself increased ACTH and cortisol, further sup porting the hypothesis that pindolol is not a pure 5-HT 1a antagonist (FG Moeller, unpublished data).
Although it is possible that the buspirone-induced prolactin response may be secondary to effects on DA, buspirone does have a high affinity for the 5-HT 1a receptor subtype (Peroutka 1985; Yocca et al. 1986 Yocca et al. , 1990 , where buspirone acts as a partial agonist (Yocca et al. 1986 ). Buspirone also lacks the behavioral, or mo tor, effects common to DA antagonists. Buspirone has been found to increase serum ACTH and cortisol and to decrease temperature in rats and humans (Cowen et al. 1990; Koenig et al. 1988) . These effects are similar to the effects of 8-0H-DPAT (the prototypical 5-HT 1a receptor agonist) in rats (Gilbert et al. 1988; Aulakh et al. 1988) . Buspirone also increases serum prolactin in both laboratory animals and man (Meltzer et al. 1982 (Meltzer et al. , 1983 Cowen et al. 1990 ), similar to the 5-HT -releasing agent fenfluramine (Serri et al. 1987; Coccaro et al. 1988; Siever et al. 1984; Quattrone et al. 1983) , and the 5-HT precursors L-tryptophan and 5-HTP (Lamberts et al. (1978; MacIndoe et al. 1973) .
The fact that the buspirone-induced prolactin re sponse is not blocked by pindolol and the fact that other serotonin agonists do not appear to induce the degree of elevation in prolactin that buspirone does leads to the conclusion that at least part of the prolactin response induced by buspirone is probably mediated by buspi rone's effects as a DA antagonist. However, due to the lack of a selective 5-HT 1a antagonist and the fact that bus pirone does not exhibit the behavioral effects of other DA antagonists, the exact relationship between 5-HT, DA, and the prolactin response to buspirone re mains undetermined.
A relationship between DA and MDD was postu lated over 15 years ago (Randrup et al. 1975) . The strong est biochemical evidence for this relationship comes from studies examining cerebrospinal fluid homovanil lic acid. Several studies fmd decreased cerebrospinal fluid homovanillic acid in patients with depression (Goodwin et al. 1973; Randrup et al. 1975; van Praag et al. 1975) . However, because this abnormality is most pr onounced in patients with psychomotor retardation (Kapur and Mann 1992) , it is unclear whether low cerebrospinal fluid homovanillic acid is related to depression itself or to accompanying psychomotor retardation. The questions regarding the relationship be tween DA and depression are compounded by the fact that most studies using DA agonists as neuroen do crine challenge agents do not fmd evidence of ab normal DA function in depression (Costain et al. 1982; Christie et al. 1982 , Balldin et al. 1982 ).
In summary, we report a blunted prolactin response to bus pirone neuroendocrine challenge in patients with MDD compared to healthy controls.
The results of this study should be viewed as pre liminary, in light of the small sample size, and the pos sible influence of bus pirone's effects on DA. However, in light of other studies that fmd evidence of a 5-HT1a defIcit in MDD, this study does support further inves tigation into the specifIc role of the presynaptic and post synaptic 5-HT 1a receptors in the etiology of MDD.
